← All trials
NCT04857840
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 5, 2021
- Primary completion
- Sep 20, 2023
- Completion date
- Jul 21, 2024
- First posted
- Apr 23, 2021
- Last posted
- Sep 20, 2021
- Enrollment
- 750
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Quantum Genomics SALead sponsor
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
- University of ChicagoStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.